Guggenheim maintains Neurocrine Biosciences at Buy, raises price target to $224 from $207
Guggenheim reaffirmed its Buy rating for Neurocrine Biosciences and increased its price target to $224 from $207, suggesting a 35.9% upside from the Nov 3 close of $164.85. Recent analyst price targets for the company range from $185 to $220.
How this was made
The 30-second read
Why it matters
The upgrade may trigger buying interest, but the effect could be muted if the market has already priced in expectations.
Market read
A modest analyst upgrade that could generate short-term upside for NBIX.
What to watch
Potential regulatory or trial setbacks could negate the upside.
Background
Analyst price target updates are common catalysts for short-term price moves.
Ticker impact
Guggenheim raised Neurocrine Biosciences price target to $224 from $207.
potential upside as investors price in the higher target.
Target increase signals improved outlook, likely prompting buying pressure.
Market effects
Biotech sector may see modest lift from analyst optimism.
U.S. biotech stocks could benefit from the upgrade.
Limited to investors tracking Neurocrine and related biotech peers.
Counterpoint
Target raise may be premature if upcoming trial data disappoints.
Key entities
- Analyst FirmGuggenheim
Provided the upgraded price target.
- CompanyNeurocrine Biosciences
Subject of the price target upgrade.
